Furthermore, as in RA, IL-1 targeted therapies have already been shown to improve CV outcomes in clinical trials in patients with or at risk for myocardial infarction, heart failure, and recurrent pericarditis4,5. The gene discussed is IL1A; the disease is rheumatoid arthritis.